US FDA approves nivolumab immunotherapy for liver cancer
Liver fibrosis speeds up around the menopause in women with HIV and HCV co-infection
People with HIV are at risk for liver fibrosis and steatosis
Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV
Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors
New AbbVie hepatitis C combination cures 99% of people with cirrhosis
Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants
Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?
